IRF1 Deficiency: Comprehensive Research Report

1. Disease Information

Overview. IRF1 deficiency is a recently characterized (2023) autosomal recessive inborn error of immunity caused by biallelic loss-of-function variants in IRF1 (Interferon Regulatory Factor 1). It presents as a novel genetic etiology of Mendelian Susceptibility to Mycobacterial Disease (MSMD), a heterogeneous group of inborn errors of immunity in which otherwise healthy children develop severe, disseminated disease caused by weakly virulent mycobacteria — the BCG vaccine strain (Mycobacterium bovis BCG) and environmental (nontuberculous) mycobacteria (EM) — and related "intramacrophagic" pathogens, in the absence of notable susceptibility to other classes of pathogens (PMC9907019, Rosain et al., Cell, 2023; PMID: 36736301). The defect is selective: IRF1-deficient patients show no history of severe viral disease despite documented exposure to multiple viruses, including SARS-CoV-2, distinguishing this condition mechanistically from broader antiviral interferon disorders (PMC9907019).

Key identifiers: - Gene: IRF1 (HGNC:6116), chromosome 5q31.1 - OMIM gene entry: 147575 — Interferon Regulatory Factor 1; IRF1 - OMIM phenotype: #620668 — Immunodeficiency 117 (IMD117) - Orphanet: ORPHA:699615 — "Complete IRF1 deficiency," listed under the MSMD gene/disease group (orpha.net/en/disease/gene/IRF1) - Disease category: Mendelian, primary/inborn immunodeficiency; a subtype within the MSMD spectrum (~21 known genetic etiologies) - Common synonyms/alternative names:* Immunodeficiency-117 (IMD117); Complete IRF1 deficiency; MSMD due to IRF1 deficiency; IRF1-related mycobacterial susceptibility

Evidence basis. As a disease first described in a single primary-literature report, essentially all current knowledge derives from aggregated case-series/mechanistic study data (two unrelated index patients studied in depth with genomics, immunophenotyping, transcriptomics, and cellular functional assays), rather than large-scale EHR/registry data. OMIM's clinical synopsis for IMD117 (#620668) is itself abstracted directly from this same primary report.

2. Etiology

Primary cause. IMD117 is caused by homozygous (biallelic) loss-of-function nonsense mutations in IRF1, identified in two unrelated children, each born to consanguineous parents (PMC9907019; OMIM #620668): - Patient 1: homozygous c.385C>T, p.Arg129Ter (R129X) - Patient 2 (girl): homozygous c.103C>T, p.Gln35Ter (Q35X)

Both variants were identified by whole-exome sequencing and segregated with disease in each family, consistent with autosomal recessive inheritance. Functional testing showed the R129X truncated protein still localizes to the nucleus and retains DNA-binding capacity but has no transcriptional activity; patient cells showed markedly reduced IRF1 mRNA (consistent with nonsense-mediated decay) and absent IRF1 protein, confirming a complete loss-of-function/null mechanism rather than a dominant-negative one.

Risk factors: - Genetic: Biallelic (homozygous) null variants in IRF1 are causal and fully penetrant for the mycobacterial phenotype reported to date. Consanguinity was present in both reported families, consistent with the ultra-rare autosomal recessive inheritance model and elevated homozygosity risk in consanguineous unions. - Environmental/exposure: BCG vaccination is the dominant precipitating exposure worldwide (given routinely in many countries with high TB burden), producing disseminated "BCGitis/BCGosis." Environmental (nontuberculous) mycobacteria exposure (e.g., Mycobacterium avium complex) is the other principal trigger. - No modifier genes or protective variants have yet been reported for IRF1 deficiency specifically, reflecting its very recent discovery and the extremely small number of known patients (n=2 in the founding report).

Gene-environment interaction. The disease is a classic "genotype reveals susceptibility to an otherwise low-virulence environmental/vaccine exposure" model typical of MSMD: the germline defect is silent until the child is exposed to BCG (via routine immunization) or to ubiquitous environmental mycobacteria, at which point unchecked intramacrophagic replication produces disseminated disease.

3. Phenotypes

Core clinical phenotype: early-onset, recurrent, multifocal/disseminated disease due to weakly virulent mycobacteria — both BCG (post-vaccination) and environmental mycobacteria — in patients who otherwise lack a striking susceptibility to viral, fungal, or ordinary bacterial pathogens (PMC9907019; OMIM #620668).

Phenotype characteristics: - Onset: Early childhood (infancy/early childhood), typically following BCG vaccination - Course: Recurrent, life-threatening, multifocal mycobacterial disease episodes; disease persisted/recurred despite treatment with multiple antimycobacterial drugs, indicating a severe underlying immunologic defect rather than antimicrobial resistance - Severity: Severe/life-threatening in both reported patients - Frequency: Based on n=2 patients (extremely rare); disseminated mycobacterial disease is essentially fully penetrant in the biallelic null genotype reported

Laboratory/immunologic phenotype (a distinct "laboratory abnormality" phenotype class): - Mildly impaired IFN-γ secretion by leukocytes - Impaired cellular response to IFN-γ in fibroblasts and myeloid cells, with impaired signaling downstream of STAT1 - Deficient expression of IFN-γ-inducible genes involved in immune activation and antimicrobial effector function - Impaired development of T and NK cell subsets on transcriptome analysis, with abnormal expression of NK/T developmental target genes - Normal responses to type I interferon (IFN-α/β) and normal in vitro antiviral activity against several pathogens, including SARS-CoV-2 — the key finding establishing IRF1's redundancy for antiviral immunity in humans despite being essential for antimycobacterial immunity

Quality of life impact: Not formally studied (no EQ-5D/SF-36 data available for this ultra-rare, recently described condition); qualitatively, disease burden is high given recurrent life-threatening infection episodes in early childhood requiring prolonged multidrug antimycobacterial therapy.

Suggested HPO terms: - HP:0002718 — Recurrent infections - HP:0002090 — Pneumonia (if pulmonary involvement) - HP:0100646 — Abnormal lymph node morphology / lymphadenopathy (BCGitis-associated) - HP:0410030 — Impaired lymphocyte transformation / abnormal T-cell physiology (developmental impairment of T/NK cells) - HP:0040312 — (or nearest available) susceptibility to mycobacterial infection — note: dismech curators should check for the most specific MSMD-family HPO term, as HPO's coverage of "mycobacterial disease susceptibility" is coded at varying granularity across MSMD gene entries - HP:0002960 — Autoimmunity / immune dysregulation — not reported in IRF1 deficiency to date; include only if literature review of later case reports confirms

(GeneCards reports IRF1 as linked to 38 HPO terms across multiple organ systems in aggregate gene-disease association databases, but the two published human IRF1-deficiency cases are specifically and narrowly characterized by mycobacterial/immune phenotypes; broader multi-system associations in aggregator databases likely reflect somatic/oncologic IRF1 biology rather than the germline immunodeficiency phenotype and should be curated cautiously.)

4. Genetic/Molecular Information

Causal gene: IRF1, HGNC:6116, OMIM *147575, chromosome 5q31.1.

Pathogenic variants identified to date (both from the founding report, PMC9907019 / OMIM #620668):

• Variant classification: Both variants function as complete loss-of-function (null) alleles based on segregation with a fully recessive Mendelian phenotype plus direct functional/biochemical confirmation (loss of transcriptional activity in reconstitution assays; absent protein in patient cells) — consistent with ACMG/AMP "pathogenic" classification, though formal ClinVar submission status was not independently confirmed in this research pass.
• Origin: Both are germline variants (not somatic); both patients born of consanguineous parents, consistent with homozygosity by descent.
• Functional consequence: Complete loss of function — no dominant-negative or gain-of-function mechanism identified. IRF1's role as a transcriptional activator downstream of IFN-γ/STAT1/GAF signaling is abolished.
• Population allele frequency: Formal gnomAD constraint statistics (pLI/LOEUF/o-e ratio) for IRF1 were not retrievable in this pass and should be queried directly at gnomad.broadinstitute.org before curation; given IRF1's dual roles as an immune transcription factor and tumor suppressor (see below), even heterozygous LoF carriers are of interest for constraint modeling, but no disease association has been reported for heterozygous carriers of these specific null alleles.

Modifier genes: None reported specifically for IRF1 deficiency; not enough patients have been described to assess phenotypic variability or modifiers.

Somatic/oncologic genetics (distinct from the germline immunodeficiency, but relevant gene biology): IRF1 was originally identified as a candidate myeloid tumor-suppressor gene at 5q31.1, one of the most frequently deleted regions in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), particularly del(5q)/5q− syndrome (Willman et al., Science, 1993; PMID: 8438156). IRF-1 was the only gene in the smallest commonly deleted region consistently lost (mono- or bi-allelically) across 13 leukemia/MDS cases with 5q31 aberrations. IRF-1 expression is lost in acute promyelocytic leukemia and a subset of AML with del(5)(q31) (Nature Leukemia, PMID search results). In mouse models, Irf1 loss dramatically exacerbates tumor development in HRAS-transgenic and p53-null backgrounds, establishing a functional interaction between IRF1 loss and p53-pathway tumor suppression (Genes Dev., PMID search results). This tumor-suppressor biology is mechanistically separate from — but molecularly continuous with — the germline immunodeficiency phenotype, since both derive from loss of IRF1's transcriptional activator function (in one case over growth/apoptosis genes, in the other over IFN-γ-response genes).

Epigenetic information: No disease-specific epigenetic (DNA methylation/histone modification) data for germline IRF1 deficiency were identified in this pass; IRF1 promoter hypermethylation/silencing has been studied in cancer contexts but is outside the scope of the germline immunodeficiency entry.

Chromosomal abnormalities: Not applicable to the germline immunodeficiency (point/nonsense variants only); large-scale 5q31 deletions encompassing IRF1 are a somatic/oncologic finding (see above), not a germline immunodeficiency mechanism.

5. Environmental Information

• Environmental factors: Exposure to environmental (nontuberculous) mycobacteria (e.g., Mycobacterium avium complex, and related species such as M. fortuitum) is a primary environmental trigger of clinical disease in genetically susceptible individuals.
• Iatrogenic/programmatic exposure: BCG vaccination, administered routinely in many countries as part of childhood immunization against tuberculosis, is the principal identified precipitant of disease onset in both reported IRF1-deficient patients, producing disseminated "BCGitis" (localized-to-disseminated M. bovis BCG disease).
• Infectious agents implicated:
• Mycobacterium bovis BCG vaccine strain (NCBI Taxonomy: relevant to M. bovis subsp. BCG)
• Environmental/nontuberculous mycobacteria broadly, with M. avium complex specifically implicated in mechanistic literature on IRF1's role in macrophage control of mycobacteria (e.g., mBio 2021 study on TNF-α/IL-6 autocrine signaling inducing IRF1/IRG1 in M. avium-infected human macrophages)
• Lifestyle factors: Not applicable/not reported — this is a pediatric, genetically determined susceptibility rather than a lifestyle-modulated condition.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic nonsense variants in IRF1 (e.g., Q35X, R129X) lead to loss of full-length IRF1 protein — via nonsense-mediated mRNA decay and/or production of a transcriptionally inert truncated protein.
2. Following exposure to BCG or environmental mycobacteria, innate immune cells (monocytes/macrophages, NK cells) and T cells mount an IL-12/IL-23-driven IFN-γ response, which normally engages IFNGR1/IFNGR2 → JAK1/JAK2 → STAT1 (GAF complex) signaling. This upstream IFN-γ/STAT1 axis remains largely intact in IRF1 deficiency (patients show only mild impairment of IFN-γ secretion).
3. Physiologically, GAF-activated STAT1 induces IRF1 transcription and nuclear translocation, where IRF1 binds ISRE-like motifs in target-gene promoters as the "second wave" effector of the IFN-γ response, downstream of and largely dependent on STAT1.
4. In IRF1 deficiency, this second wave fails to occur: IRF1 loss abolishes transcriptional induction of roughly one-third of all IFN-γ-inducible mRNAs, including a large fraction of genes previously shown to be essential for cell-intrinsic immunity to intracellular pathogens (PMC9907019 — "IRF1 controlled the expression of one-third of IFN-γ-inducible mRNAs, including numerous targets previously described as essential for cell-intrinsic immunity to intracellular pathogens").
5. Among the genes that fail to be upregulated are classical IRF1 targets encoding antimicrobial effectors and antigen-presentation machinery: inducible nitric oxide synthase (NOS2/iNOS), guanylate-binding proteins (GBP2, GBP5), the immunoproteasome subunits (PSMB9/LMP2), and the peptide transporter (TAP1), together with CIITA (the MHC class II transactivator) and components of MHC class I antigen-processing/presentation (PMC4398980; Genes & Immunity/Regulation of Tap1/Lmp2; ScienceDirect CIITA induction data).
6. Loss of these antimicrobial effectors directly impairs the intrinsic mycobactericidal/mycobacteriostatic capacity of macrophages — this is the proximate lesion: "IRF1-deficient mononuclear macrophages do not control mycobacteria or related intramacrophagic pathogens normally in response to IFN-γ" (PMC9907019).
7. In parallel, transcriptomic analysis of patient cells shows impaired development of T and NK cell subsets that normally secrete and respond to IFN-γ, with abnormal expression of NK/T lineage developmental target genes — recapitulating findings from Irf1-knockout mice (see Model Organisms, below), where IRF1 acts non-cell-autonomously via the bone-marrow stromal microenvironment (through IL-15 induction) to support NK-cell development, and cell-autonomously to support Th1/CD8+ T-cell differentiation and IL-12-driven maturation.
8. The net result is a selective collapse of the "IFN-γ circuit" required to arm macrophages against intracellular mycobacteria, without compromising the largely IRF1-independent type I interferon (IFN-α/β) antiviral circuit — explaining the clinical pattern of severe, recurrent mycobacterial disease with preserved antiviral competence, including normal in vitro control of SARS-CoV-2.

Molecular pathways

IFN-γ → IFNGR1/IFNGR2 → JAK1/JAK2 → STAT1 (GAF) → IRF1 induction → IRF1 binding to ISRE/IRF-E motifs → transcription of antimicrobial and antigen-presentation genes. This sits within the broader IL-12/IL-23–IFN-γ axis that defines MSMD pathobiology generally (Frontiers Immunol. 2026 review, "IFN-γ-driven immunity collapse underlies heterogeneous infections"; PMC12255513 MSMD overview). Suggested GO terms: GO:0060333 (interferon-gamma-mediated signaling pathway), GO:0071346 (cellular response to interferon-gamma), GO:0002218 (activation of innate immune response), GO:0140374 (antiviral innate immune response — for the preserved arm).

Cellular processes

• Failure of macrophage-intrinsic antimycobacterial killing programs (nitric oxide production, GBP-mediated vacuolar disruption of intracellular pathogens)
• Impaired NK-cell and T-cell developmental programming
• Preserved apoptosis/cell-death and type I IFN antiviral programs

Protein dysfunction

Complete loss of function of the IRF1 transcription factor. IRF1 possesses an N-terminal winged helix-turn-helix DNA-binding domain built from five tryptophan-rich repeats, which recognizes tandem GAAA ISRE half-site motifs (structurally defined via the 1998 IRF1-DBD/DNA crystal structure, PDB 1IF1; PMID: 9422515), and a C-terminal IRF-association domain (IAD) mediating cofactor interactions. The R129X truncation retains DNA binding but loses transactivation capacity entirely (no downstream transcription), while Q35X essentially eliminates the protein via nonsense-mediated decay — both converging on a null functional outcome.

Immune system involvement

This is fundamentally an immunodeficiency mechanism (not autoimmunity): a selective, IFN-γ-restricted intrinsic immunodeficiency of macrophages, compounded by an NK/T-cell developmental defect, producing susceptibility specifically to intramacrophagic pathogens (mycobacteria) while leaving humoral immunity, IFN-α/β antiviral immunity, and general bacterial defenses comparatively intact.

Tissue damage mechanisms

Disease manifests as granulomatous/suppurative disseminated mycobacterial lesions (lymphadenitis, osteomyelitis, and other classic BCGitis/disseminated-EM patterns typical of MSMD), reflecting failure to contain — rather than actively destructive autoinflammatory — pathology.

Molecular profiling

Transcriptome (RNA-seq) analysis of patient leukocytes/fibroblasts was central to establishing the ~1/3 reduction in IFN-γ-inducible gene induction and to demonstrating the T/NK developmental gene-expression signature (PMC9907019). No single-cell, spatial, proteomic, metabolomic, or CRISPR-screen data specific to IRF1-deficient patients were identified in this research pass; the founding paper's genome-wide IRF1 chromatin-binding data in normal cells (ChIP-seq, PMC4398980, "Genome-wide Identification of IRF1 Binding Sites Reveals Extensive Occupancy at Cell Death Associated Genes") is a relevant reference dataset for target-gene identification but was performed in reference (non-patient) cells.

7. Anatomical Structures Affected

• Organ level (primary): Reticuloendothelial/lymphoid system (lymph nodes — BCGitis lymphadenitis), and any site of disseminated mycobacterial seeding (skin/soft tissue, bone, lung, liver, spleen), consistent with typical MSMD disease distribution.
• Secondary organ involvement: Determined by the pattern of disseminated infection in each patient (site-specific granulomatous disease); not exhaustively itemized in available secondary sources for this research pass — primary literature (PMC9907019) should be consulted directly for patient-level organ involvement detail during curation.
• Body systems involved: Immune system (primary); secondarily, whichever organ systems harbor disseminated mycobacterial foci.
• Tissue/cell level: Macrophages/monocytes (the principal cell-intrinsic site of the antimycobacterial defect) and NK cells / T lymphocytes (developmental defect). Suggested Cell Ontology terms: CL:0000235 (macrophage), CL:0000576 (monocyte), CL:0000623 (natural killer cell), CL:0000084 (T cell).
• Subcellular level: Nucleus (site of IRF1 transactivation of target genes; also site of the transcriptionally-inert truncated R129X protein); GO Cellular Component: GO:0005634 (nucleus), GO:0000785 (chromatin, where IRF1 binds ISRE elements).
• Localization/laterality: Not applicable — systemic/disseminated pattern rather than lateralized.

Suggested UBERON terms: UBERON:0000178 (blood), UBERON:0002370 (thymus, relevant to T-cell development), UBERON:0002370/0001744 (lymph node), UBERON:0002107 (liver), UBERON:0002106 (spleen) as applicable per patient-level detail.

8. Temporal Development

• Onset: Early childhood; disease manifested following BCG vaccination (typically administered in infancy in BCG-endemic countries), consistent with the general MSMD onset pattern of early-childhood presentation.
• Onset pattern: Insidious-to-acute presentation of disseminated mycobacterial disease following exposure/vaccination.
• Progression: Recurrent — both reported patients experienced recurrent, life-threatening episodes caused by multiple mycobacteria (both BCG and environmental mycobacteria), despite treatment with multiple antimycobacterial drugs, indicating a chronic, relapsing disease course rather than a single self-limited event.
• Disease course pattern: Chronic/relapsing, driven by an underlying immunologic defect rather than antimicrobial resistance; unlike the classical progressive neurodegenerative or metabolic Mendelian disease pattern, MSMD/IRF1 deficiency is punctuated by infection episodes whose severity/frequency is a function of ongoing pathogen exposure.
• Duration: Chronic, lifelong immunologic susceptibility (the genetic lesion is permanent); clinical episodes may remit with antimycobacterial treatment but recur on re-exposure or reactivation given the failure of intrinsic macrophage control.
• Critical periods: Early childhood BCG vaccination represents a clear "critical exposure window" — in countries that do not administer BCG, or where BCG is delayed/omitted in known carriers, initial presentation may instead follow environmental mycobacterial exposure at a variable age.

No formal staging system, remission-pattern data, or natural-history/longitudinal cohort data exist yet for this ultra-rare, recently described condition (n=2 patients in the literature to date).

9. Inheritance and Population

• Epidemiology: IRF1 deficiency is an ultra-rare condition; only two patients from two unrelated families have been reported in the literature to date (as of the founding 2023 report), and no population-level prevalence or incidence estimates exist. MSMD broadly is itself a rare disease group (~21 known genetic causes) with substantial but incompletely quantified global prevalence, concentrated in populations with high consanguinity rates and routine BCG vaccination programs.
• Inheritance pattern: Autosomal recessive — both index cases were homozygous for their respective nonsense variants, each inherited from consanguineous parents, consistent with recessive segregation.
• Penetrance: Appears complete for the mycobacterial-susceptibility phenotype in both reported homozygous patients (both alleles are functionally null), though the extremely small sample size precludes firm penetrance/expressivity estimates.
• Expressivity: Not yet characterized due to small patient number; both patients shared the core disseminated-BCG/environmental-mycobacteria phenotype.
• Genetic anticipation: Not applicable — nonsense variants, not a repeat-expansion mechanism.
• Germline mosaicism: Not reported.
• Founder effects: Not established; the two reported variants (Q35X, R129X) arose independently in unrelated consanguineous families, with no shared haplotype reported in available sources.
• Carrier frequency: Not established in population databases for these specific null alleles at the time of this research pass; should be checked directly in gnomAD during curation.
• Consanguinity role: Central — both reported families were consanguineous, the expected pattern for an ultra-rare autosomal recessive null-allele disease.
• Population demographics: Insufficient data (n=2) to characterize ethnic/geographic distribution, sex ratio, or age distribution beyond noting both cases presented in early childhood consistent with the general MSMD pattern; one reported patient was female (Q35X carrier).

10. Diagnostics

• Clinical suspicion: A child presenting with disseminated or unusually severe disease due to BCG vaccine strain or environmental/nontuberculous mycobacteria, particularly with consanguineous parentage or recurrent/refractory disease despite standard antimycobacterial therapy, should prompt evaluation for an MSMD-spectrum genetic defect.
• Genetic testing (primary diagnostic modality):
• Whole-exome sequencing (WES) was the method used to identify both reported causal IRF1 variants and is the appropriate first-line broad genetic test given the ~21 known and expanding list of MSMD genes.
• Targeted MSMD/primary-immunodeficiency gene panels including IRF1, alongside the more common MSMD genes (IL12RB1, IFNGR1, IFNGR2, STAT1, IL12B, ISG15, IRF8, NEMO/IKBKG, RORC, JAK1, TYK2, SPPL2A, TBX21, etc.), are a practical clinical option.
• Single-gene IRF1 Sanger confirmation following identification of a candidate variant, plus segregation analysis in the family.
• Functional/immunologic testing:
• IFN-γ secretion assays (whole-blood or PBMC stimulation) — expect mild impairment
• Cellular response to exogenous IFN-γ (STAT1 phosphorylation and downstream target-gene induction, e.g., in fibroblasts) — expect impaired downstream (post-STAT1) signaling with intact proximal STAT1 phosphorylation, localizing the defect to the IRF1 "second wave"
• Immunophenotyping of NK and T-cell subsets — expect reduced/abnormal NK and T-cell development on flow cytometry, correlating with the transcriptomic findings
• IRF1 protein expression by Western blot/immunoblot in patient-derived cells — expect absent protein
• Histopathology: Granulomatous inflammation typical of mycobacterial disease at biopsied sites (e.g., lymph node), non-specific to IRF1 deficiency per se but supportive of the overall clinical picture.
• Differential diagnosis: Other MSMD gene defects (IL12RB1 — most common cause of AR MSMD; IFNGR1/IFNGR2 deficiency; STAT1 deficiency; IRF8 deficiency; RORC deficiency; JAK1 deficiency; complete or partial forms across this gene list) must be excluded/distinguished by genetic testing, as clinical presentations overlap substantially. IFNγR1/R2 deficiency in particular can mimic the phenotype but differs in whether IFN-γ therapy is beneficial.
• Screening: No population-based newborn screening exists for this ultra-rare condition; genetic counseling and carrier/cascade testing in consanguineous families with an index case is the appropriate secondary-prevention measure. Given the mechanistic importance of BCG vaccination as a trigger, family history of BCG-related disease in a consanguineous kindred could in principle prompt genetic testing before vaccinating at-risk relatives, though no formal screening protocol has been published specific to IRF1.

Suggested NCIT/LOINC terms: NCIT:C15709 (Genetic Testing), general WES/panel testing codes; disease-specific IRF1 diagnostic assay codes are not yet standardized.

11. Outcome/Prognosis

• Survival/mortality: No IRF1-deficiency-specific survival statistics exist given the tiny reported cohort (n=2); broadly, MSMD mortality ranges from ~40% to 80% depending on the severity of the underlying genetic defect (general MSMD literature, PMC12255513 overview), with complete/null genotypes (as in both reported IRF1 cases) generally correlating with more severe disease within the MSMD spectrum, though direct IRF1-specific mortality figures are not yet published.
• Disease course: Recurrent, life-threatening mycobacterial disease episodes despite multidrug antimycobacterial therapy in both reported patients — indicating that antimicrobial therapy alone is often insufficient to fully control disease given the underlying failure of intrinsic macrophage antimycobacterial defense.
• Complications: Disseminated granulomatous disease at multiple anatomic sites (as is typical across MSMD); specific organ-failure or long-term sequela data for IRF1 deficiency were not available in the sources reviewed here.
• Recovery potential: Because the defect is selectively restricted to the IFN-γ/macrophage antimycobacterial axis (with preserved IFN-α/β antiviral immunity), prognosis may in principle be more favorable for this arm of immunity than for MSMD defects with broader combined immunodeficiency; however, this has not been formally studied.
• Prognostic factors: Genotype (complete/null vs. partial loss-of-function) is the dominant prognostic determinant across the MSMD gene family generally, by analogy; both reported IRF1 variants are complete-null alleles.

12. Treatment

• Antimycobacterial pharmacotherapy: Standard multidrug antimycobacterial regimens (e.g., combinations from rifamycins, macrolides, ethambutol, and other antimycobacterial agents used per pathogen and susceptibility) were used in both reported patients, but disease recurred despite this treatment, underscoring the need for immune-directed or curative approaches in confirmed genetic MSMD (NCIT:C15632/Chemotherapy is not the correct category — use NCIT:C15986 Pharmacotherapy for antimycobacterial drug therapy in general).
• Interferon-gamma (IFN-γ) therapy: Recombinant human IFN-γ is used across the MSMD spectrum in patients with impaired IFN-γ production (as opposed to impaired IFN-γ response), and has been specifically noted as a treatment approach applied in IRF1 deficiency in general MSMD treatment literature, though its efficacy in a defect that acts downstream of/parallel to STAT1 signaling (rather than at the level of cytokine production) is mechanistically less clearly predicted to be curative than in cytokine-production defects — this nuance should be flagged for careful sourcing at the individual-patient level during curation. NCIT term: consider NCIT:C1666 (Interferon Gamma) as therapeutic_agent, with treatment_term NCIT:C15986 (Pharmacotherapy).
• Hematopoietic stem cell transplantation (HSCT): Across the MSMD gene family, HSCT is the only known curative treatment, particularly indicated when the underlying defect abolishes response to IFN-γ rather than merely impairing its production (general MSMD literature; PMC/Orphanet MSMD sources). Given that IRF1 deficiency acts by abolishing the transcriptional response to IFN-γ in myeloid cells (i.e., a response defect, not solely a production defect), and given the demonstrated impairment of hematopoietic/immune cell development (T/NK cells), HSCT is mechanistically a rational candidate curative therapy, though no published outcome data for HSCT specifically in an IRF1-deficient patient were identified in this research pass.
• Surgical/interventional: Surgical debridement/drainage of localized suppurative or abscessed mycobacterial lesions (e.g., BCGitis lymphadenitis) may be used adjunctively, as in MSMD generally (NCIT:C15329, Surgical Procedure).
• Supportive care: General infection-related supportive care as clinically indicated.
• Experimental/investigational: No IRF1-deficiency-specific clinical trials (NCT identifiers) were identified in this research pass; patients would likely be considered, on a compassionate/individual basis, within broader primary-immunodeficiency/MSMD HSCT protocols.
• Treatment strategy: As with other MSMD defects, treatment algorithms hinge on distinguishing IFN-γ production defects (favoring recombinant IFN-γ) from IFN-γ response defects (favoring HSCT), and on genotype-specific severity — IRF1 deficiency, as a downstream transcriptional response defect with combined myeloid-functional and lymphoid-developmental impairment, likely sits closer to the "response defect, consider HSCT" end of this spectrum, though direct outcome evidence in IRF1-deficient patients remains to be published.

13. Prevention

• Primary prevention: The most clinically actionable primary-prevention consideration is avoidance or deferral of BCG vaccination in infants known (by prior family genetic diagnosis) to be at risk of biallelic IRF1 (or other MSMD-gene) null variants, given that BCG vaccination was the precipitating exposure in reported cases. This mirrors established practice for other severe combined and MSMD-spectrum immunodeficiencies in which live vaccines are contraindicated.
• Genetic counseling: Essential in consanguineous families with an index case, given the autosomal recessive inheritance and elevated recurrence risk (25% per pregnancy for parents who are both carriers); prenatal or preimplantation genetic testing may be offered where the familial variant is known.
• Secondary prevention/screening: Cascade genetic testing of siblings/relatives in an affected consanguineous kindred, prior to BCG vaccination or other live-pathogen exposures, is the principal secondary-prevention strategy, though no formal published screening protocol specific to IRF1 deficiency exists.
• Tertiary prevention: Prompt recognition and multidrug antimycobacterial therapy at first presentation, with early consideration of curative HSCT, to prevent recurrent/progressive disseminated disease.
• Environmental/public health interventions: General avoidance of high-risk environmental mycobacterial exposures is a nonspecific consideration common to all MSMD patients but has not been formally studied for IRF1 deficiency specifically.

14. Other Species / Natural Disease

No naturally occurring IRF1-deficiency disease has been reported in non-human species in the sources reviewed for this report. IRF1 orthologs are broadly conserved across mammals (see Model Organisms below), and cross-species comparative-pathology or veterinary case data specific to spontaneous IRF1 loss-of-function disease were not identified in this research pass; if curating this section further, OMIA (Online Mendelian Inheritance in Animals) and veterinary case-report literature should be searched directly, as none surfaced here.

15. Model Organisms

Primary model: Irf1-knockout (Irf1⁻/⁻) mouse (JAX strain 002762), which has been extensively used to define IRF1 immune biology well before the human disease was described, and whose phenotype strongly recapitulates and mechanistically anticipates the 2023 human findings:

• NK cell development: Irf1⁻/⁻ mice show strongly reduced NK cell numbers. Mechanistically, IRF1 acts non-cell-autonomously: it is required in the radiation-resistant bone-marrow stromal microenvironment (via induction of IL-15) to support NK-cell development, not in the NK-cell progenitors themselves — Irf1⁻/⁻ bone-marrow cells can generate functional NK cells when cultured with exogenous IL-15 (PMID: 9490414, "Requirement for IRF-1 in the microenvironment supporting development of natural killer cells"). NK-cell cytotoxicity and IFN-γ secretion (particularly after IL-12 stimulation) are abrogated.
• T-cell/Th1 development: Irf1⁻/⁻ mice show impaired CD8+ T-cell and NK-cell maturation, impaired IL-12 production by macrophages, exclusive Th2 skewing, and defective Th1 differentiation.
• Antigen presentation: Irf1⁻/⁻ mice lack expression of gene products involved in antigen presentation (consistent with IRF1's role in inducing TAP1, LMP2/PSMB9, and CIITA), compounding the Th1/NK/CD8 defects into a broader immunodeficient phenotype.
• Fidelity to human disease: The mouse model recapitulates the key human findings — impaired NK/T development, impaired IL-12/IFN-γ axis function, and impaired antigen-presentation gene induction — providing strong mechanistic support (HIGH-to-MODERATE fidelity) for the human transcriptomic finding of impaired T/NK developmental gene expression. A notable divergence/translational caveat: the mouse literature identifies the NK-cell defect as stromal-microenvironment-driven (via IL-15) rather than NK-progenitor-intrinsic — whether this same non-cell-autonomous mechanism explains the T/NK developmental abnormality reported in human IRF1-deficient patients has not yet been directly tested and should be flagged as an open question (a candidate HUMAN_MODEL_MISMATCH-type consideration for dismech curation) rather than assumed.
• Tumor-suppressor phenotype in mice: Irf1⁻/⁻ mice crossed onto HRAS-transgenic or p53⁻/⁻ backgrounds show markedly increased tumor susceptibility, supporting IRF1's tumor-suppressor role independent of, but molecularly convergent with, its immune function (Genes Dev., PMID search results).

Suggested GO/CL/NCBITaxon terms: NCBITaxon:10090 (Mus musculus); CL:0000623 (natural killer cell); CL:0000084 (T cell); GO:0032609 (interferon-gamma production); GO:0002250 (adaptive immune response).

Other model systems: No zebrafish, Drosophila, C. elegans, yeast, organoid, or iPSC-derived model systems specific to IRF1 immunodeficiency were identified in this research pass; the mouse knockout remains the dominant and best-characterized model organism for IRF1 immune function.

Summary of Key Evidence Sources

Data gaps flagged for curators: (1) No published cases beyond the original two patients were identified as of this research pass — a targeted PubMed/ClinVar search closer to curation time is recommended to check for newer case reports (2024–2026). (2) gnomAD constraint metrics (pLI/LOEUF) for IRF1 should be pulled directly from the gnomAD browser. (3) HSCT outcome data specific to IRF1-deficient patients were not found and may not yet exist in the literature — do not assert HSCT efficacy in IRF1 deficiency without a direct primary-source citation. (4) Full clinical narrative detail (exact organs involved, ages, treatment timelines, and outcomes/survival status per patient) should be extracted directly from the Cell 2023 full text or its supplementary materials, which could not be fully retrieved as clean text in this research pass (proxy/CAPTCHA access issues) — curators should fetch the primary PDF directly for exact abstract quotes to support evidence snippets.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

• PMC:PMC9907019: "IRF1-deficient mononuclear macrophages do not control mycobacteria or related intramacrophagic pathogens normally in response to IFN-γ"
• closest text in source: "Moreover, IRF1-deficient mononuclear phagocytes do not control mycobacteria and related pathogens normally when stimulated with IFN-γ"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0100646 (1 mention) - the report calls it "Abnormal lymph node morphology / lymphadenopathy"; HP calls it Thyroiditis
• HP:0410030 (1 mention) - the report calls it "Impaired lymphocyte transformation / abnormal T-cell physiology"; HP calls it Cleft lip
• HP:0002960 (1 mention) - the report calls it "Autoimmunity / immune dysregulation — not reported in IRF1 deficiency to date"; HP calls it Autoimmunity
• GO:0000785 (1 mention) - the report calls it "chromatin, where IRF1 binds ISRE elements"; GO calls it chromatin
• UBERON:0002370 (2 mentions) - the report calls it "thymus, relevant to T-cell development"; UBERON calls it thymus
• NCIT:C1666 (1 mention) - the report calls it "Interferon Gamma"; NCIT calls it Tyrphostin A30

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002718 (1 mention) - the report calls it "Recurrent infections"; HP calls it Recurrent bacterial infections, and lists "Recurrent pyogenic infections" among its other names
• GO:0071346 (1 mention) - the report calls it "cellular response to interferon-gamma"; GO calls it cellular response to type II interferon, and lists "cellular response to gamma-interferon" among its other names
• GO:0140374 (1 mention) - the report calls it "antiviral innate immune response — for the preserved arm"; GO calls it antiviral innate immune response
• GO:0032609 (1 mention) - the report calls it "interferon-gamma production"; GO calls it type II interferon production, and lists "interferon-gamma production" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• HGNC:6116 - called "IRF1", "Gene:* IRF1"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.